Prostate Indeterminate Lesions on Magnetic Resonance Imaging-Biopsy Versus Surveillance: A Literature Review
- PMID: 29525382
- DOI: 10.1016/j.euf.2018.02.012
Prostate Indeterminate Lesions on Magnetic Resonance Imaging-Biopsy Versus Surveillance: A Literature Review
Abstract
Context: The indeterminate multiparametric prostate magnetic resonance image (mpMRI) lesion is one which cannot be classified as "positive" or "negative" for suspected cancer. Currently, there is no consensus on how to manage patients with indeterminate mpMRIs where areas cannot be classified as positives or negatives (Prostate Imaging Reporting and Data System [PI-RADS] 3 or Likert 3).
Objective: To define the concept of indeterminate lesion and describe the management strategies that may be adopted for these patients.
Evidence acquisition: A literature search of the PubMed database was performed including the search terms "prostate indeterminate lesions", "PI-RADS 3", "Likert 3", "magnetic resonance imaging", and "prostate cancer".
Evidence synthesis: There is no universally accepted definition of what constitutes an indeterminate lesion on mpMRI. This is partly due to the experience of the reporting radiologist and their willingness to call a lesion indeterminate, knowing that this may have consequences for biopsy decisions. This is also partly due to the significant variation in mpMRI acquisition parameters used between different sites. Strategies for managing the indeterminate lesion include: (1) biopsy, where there is a highly variable prevalence of prostate cancer (PCa), reflecting the differences in clinically significant PCa definitions, mpMRI protocols and interobserver variability in characterization of indeterminate lesions and (2) surveillance, where early results suggest that this strategy may be of value for some selected patients with prostate-specific antigen (PSA) monitoring and/or interval mpMRI. The use of prebiopsy MRI, in conjunction with traditional clinical parameters and secondary biomarkers-nomograms, may allow a more accurate selection of patients who can avoid biopsy.
Conclusions: A strategy of close surveillance based on PSA monitoring and interval mpMRI is a feasible management option for motivated patients with indeterminate mpMRI. This surveillance strategy could result in fewer men needing to undergo biopsy, and although early results are promising, long-term results for such a strategy are awaited.
Patient summary: In some patients who have an MRI scan of their prostate, the scan may identify an area which may or may not contain cancer. This area is typically called the "indeterminate" lesion. In this report, we attempted to define the concept of indeterminate lesion on multiparametric magnetic resonance (mpMRI) and described the strategies that may be performed for these patients. The use of mpMRI in conjunction with traditional clinical parameters may allow more accurate risk stratification and assessment of the need for prostate biopsy.
Keywords: Likert; Literature review; Magnetic resonance imaging; PI-RADS; Prostate biopsy; Prostate cancer; Prostate indeterminate lesions; Surveillance.
Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Similar articles
-
Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score.Eur Urol Focus. 2024 Jul;10(4):634-640. doi: 10.1016/j.euf.2023.10.006. Epub 2023 Oct 19. Eur Urol Focus. 2024. PMID: 37865591
-
Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.Br J Radiol. 2018 Feb;91(1083):20170645. doi: 10.1259/bjr.20170645. Epub 2017 Dec 15. Br J Radiol. 2018. PMID: 29189042 Free PMC article.
-
The Use of Multiparametric Magnetic Resonance Imaging for Follow-up of Patients Included in Active Surveillance Protocol. Can PSA Density Discriminate Patients at Different Risk of Reclassification?Clin Genitourin Cancer. 2020 Dec;18(6):e698-e704. doi: 10.1016/j.clgc.2020.04.006. Epub 2020 May 4. Clin Genitourin Cancer. 2020. PMID: 32493676
-
Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis.Eur Urol Oncol. 2021 Oct;4(5):697-713. doi: 10.1016/j.euo.2020.12.004. Epub 2020 Dec 25. Eur Urol Oncol. 2021. PMID: 33358543
-
Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis.Eur Urol. 2020 Sep;78(3):402-414. doi: 10.1016/j.eururo.2020.03.048. Epub 2020 May 20. Eur Urol. 2020. PMID: 32444265
Cited by
-
Focal therapy for localized prostate cancer: is there a "middle ground" between active surveillance and definitive treatment?Asian J Androl. 2018 Aug 31;21(1):37-44. doi: 10.4103/aja.aja_64_18. Online ahead of print. Asian J Androl. 2018. PMID: 30178774 Free PMC article.
-
Prior Negative Biopsy, PSA Density, and Anatomic Location Impact Cancer Detection Rate of MRI-Targeted PI-RADS Index Lesions.Curr Oncol. 2024 Aug 1;31(8):4406-4413. doi: 10.3390/curroncol31080329. Curr Oncol. 2024. PMID: 39195312 Free PMC article.
-
Can lesion volume and prostate-specific antigen density play a role in detecting clinically significant prostate cancer in Prostate Imaging Reporting and Data System-3 lesions on multiparametric magnetic resonance imaging?Indian J Urol. 2025 Jan-Mar;41(1):35-39. doi: 10.4103/iju.iju_112_24. Epub 2025 Jan 1. Indian J Urol. 2025. PMID: 39886626 Free PMC article.
-
The function of Prostate Health Index in detecting clinically significant prostate cancer in the PI-RADS 3 population: a multicenter prospective study.World J Urol. 2023 Feb;41(2):455-461. doi: 10.1007/s00345-022-04272-0. Epub 2023 Jan 2. World J Urol. 2023. PMID: 36592177
-
Considering Predictive Factors in the Diagnosis of Clinically Significant Prostate Cancer in Patients with PI-RADS 3 Lesions.Life (Basel). 2021 Dec 19;11(12):1432. doi: 10.3390/life11121432. Life (Basel). 2021. PMID: 34947963 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous